32 results about "Mineral ascorbates" patented technology

Use of 6-desaturated n-6 fatty acids, especially gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) or arachidonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sorbitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including prophylactic treatment), the long-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.

Compositions and methods for prevent, stabilize, reverse or treat disorders related to iron deficiency in a human or other animal. In a first embodiment, the composition includes about 10 mg to about 500 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; and about 5 mg to about 500 mg of one or more forms of an organic acid. In another embodiment, the composition includes about 50 to about 150 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; about 50 to about 250 mg of one or more forms of an organic acid; about 150 to about 250 mg of one or more forms of ascorbic acid; about 0.5 mg to about 1.5 mg vitamin B12; about 50 to about 150 mg intrinsic factor; and about 0.5 mg to about 1.5 mg folic acid.

In this invention new chemical reactions, new chemical processes are established, and these chemical reactions, chemical processes can be used with the designed system to produce nitrogen dioxide, nitric oxide and calcium ascorbate or calcium isoascorbate.The reaction vessel contains the aqueous ascorbic acid solution or aqueous isoascorbic acid solution. The temperature in the reaction vessel at the start of the reaction is at temp. 55° C. Into this solution is injected calcium nitrite dissolved in water. The gases generated by the chemical reactions are collected in the gas vessel.Here two sets of chemical reactions take place; one on the surface of the solution that produces the bulk of the gas mixture. In the liquid phase, the reactions go slow; and it gives nitric acid, calcium ascorbate and nitric oxide. Instead of calcium ascorbate one can use isoascorbate, in that case the chemical reactions will go somewhat slower.

The invention discloses a human adipose-derived stem cell serum-free basic medium. The medium uses a serum substitute, and is composed of a high glucose type DMEM basic medium, human serum albumin, transferrin, taurine, reduced glutathione, ceruloplasmin, L-ascorbic acid-2-sulfate, alpha-tocopherol succinate, linoleic acid, alpha-ketoglutarate and selenium. The serum-free basic medium can exempt potential threats caused by animal serum in conventional serum-containing mediums to human health, and the adipose-derived stem cells cultured by the medium is more suitable for clinical application.

The invention discloses a human adipose-derived stem cell serum-free basic medium. The medium uses a serum substitute, and is composed of a high glucose type DMEM basic medium, human serum albumin, transferrin, taurine, reduced glutathione, ceruloplasmin, L-ascorbic acid-2-sulfate, alpha-tocopherol succinate, linoleic acid, alpha-ketoglutarate and selenium. The serum-free basic medium can exempt potential threats caused by animal serum in conventional serum-containing mediums to human health, and the adipose-derived stem cells cultured by the medium is more suitable for clinical application.

The agent for skin external use of the present invention contains (A) tocopherol glycine esters, (B) ascorbic acid-2-phosphoric acid esters and a specific amount of (C) an anionic surface active agent having a lipopeptide structure. According to the agent for skin external use (including a cosmetic) of the present invention, it is possible to enhance stability of the tocopherol glycine esters in spite that the tocopherol glycine esters and the ascorbic acids are contained simultaneously, so that occurrence of coloring (including turbidity) and / or precipitation with time can be prevented. Therefore, efficacy and effects of the agent or the cosmetic can be well exerted over a long period of time.

This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves sequential additions of ascorbic acid and ethoxydiglycol to a first solution of vitamin in water, which are followed by addition of propylene glycol. The high stirring speed that occurs during the additions favorises a process of micronisation. Mild heating is used to achieve ascorbic acid concentrations equivalent to about 6% in 10% water or higher.

A mixture obtained by mixing ascorbic acid powder with arginine powder in a weight ratio (ascorbic acid / arginine) of 1 / 5 to 20, especially 1 / 5 to 1 / 4; and a supplement such as a nutrient preparation and a health-care food containing the mixture. Mixing of arginine powder and ascorbic acid powder in the weight ratios eliminates stringent taste specific to arginine and alleviates stringent feeling in the stomach (heartburn, nausea or vomiting) after oral intake thereof. The mixture prevents also peroxidative injuries of cells caused by an administration of a great amount of arginine alone. Further, mixing of arginine powder with ascorbic acid powder prevents browning of the mixture after long-term storage.

One of the object of the present invention is to provide an L-ascorbic acid 2-phosphate metal salt, which causes no clouding and scarcely precipitates or deposits even when added to a cosmetic material or the like having blended therein an organic acid. Disclosed herein is an L-ascorbic acid-2-phosphate metal salt with a low calcium content characterized in that the content of a calcium compound is 500 ppm or less in terms of calcium ion, and production process thereof.

The combination of compounds of the hydroxytolan family with ascorbate plus naphthoquinone (Vitamin K3; VK3), or a quinone or semiquinone analogue of VK3, kill tumor cells, inhibit tumor growth and development, and treat cancer in subjects in need thereof.

A selective chemotherapy method includes the step of contacting tumor cells with a mineral ascorbate / vitamin C metabolite composition. A chemotherapeutic composition comprises the mineral ascorbate / vitamin C metabolite composition in a pharmacologically acceptable intravenous carrier.

Compositions comprising potassium taurate bicarbonate complexes and / or potassium taurate ascorbate complexes are useful as pharmaceutical compositions and as dietary ingredients in nutritional supplements, medical foods, and other foods. In preferred embodiments, potassium taurate bicarbonate and / or potassium taurate ascorbate complexes are the active ingredient in antihypertensive drug products that are intended to lower or prevent elevated blood pressure, or as dietary ingredients in dietary supplements, medical foods or other foods that are intended to supply a source of potassium, taurine, ascorbate, and / or bicarbonate, or that are intended to help maintain normal blood pressure levels and / or normal muscle mass. In preferred embodiments, potassium taurate bicarbonate complexes are prepared by intermixing potassium bicarbonate and taurine in aqueous solutions, and potassium taurate ascorbate complexes are prepared by intermixing potassium ascorbate and taurine in aqueous solutions.

Provided is an external composition, which can eliminate the sticky feeling peculiar to salt medicines while adding L-ascorbic acid or its derivatives, and has a supple and refreshing skin feeling when used. The present invention comprises (a) thickening polysaccharides selected from any one or two or more substances selected from gellan gum, alginic acid, pectin, and carrageenan, (b) L-ascorbic acid or its derivatives , (c) alkyl-modified carboxyvinyl polymer and (d) oil components are blended together to achieve.

Provided are a dentifrice composition which comprises ascorbic acid phosphate ester or a salt thereof having outstanding stability, has a good feel when used, and has decreased buccal irritation during use and after use, and a method for stabilizing ascorbic acid phosphate ester or a salt thereof in the dentifrice composition, wherein ascorbic acid phosphate ester or a salt thereof is maintained stable over time at a pH of 8.0 or less. The dentifrice composition contains (A) ascorbic acid phosphate ester or a salt thereof, and includes (B) a silica-based abrasive and (C) an alkali metal salt selected from sodium chloride, potassium chloride, sodium sulphate, and potassium sulphate, and the dentifrice composition has a pH at 25°C of 6.0-8.0. The method for stabilizing ascorbic acid phosphate ester or a salt thereof in the dentifrice composition comprises mixing constituent (B) and also constituent (C) in the dentifrice composition containing constituent (A), and making the pH at 25°C to be 6.0-8.0.

A blood triglyceride depressant composition which comprises pravastatin and one or more members selected from the group consisting of (1) pantethine, (2) inositol hexanicotinate, (3) a combination drug containing a riboflavin compound, a tocopherol compound and an ascorbic acid compound, and (4) a combination drug containing a tocopherol compound and an ascorbic acid compound.

The invention relates to a method for preparing L-ascorbic acid or D-erythorbic acid carboxylate by using acyl chloride. According to the method, with DMAc (N,N-dimethylacetamide) or NMP (N-methyl pyrrolidone) as a solvent, a catalyst and an acid-binding agent in reaction of carboxylic acid and SOCl2, acryl chloride directly reacts with L-ascorbic acid or D-erythorbic acid without being separated to prepare L-ascorbic acid or D-erythorbic acid carboxylate. Compared with the existing acryl chloride method, the method disclosed by the invention has the characteristics of simple operation, little dosage of SOCl2, short reaction period, mild reaction conditions, high reaction yield, environmental friendliness and the like, and a used solvent does not need to be dried in advance.

The invention provides stable L-ascorbyl-2-phosphate-6-fatty acid and the salt powder preparation thereof. The invention also provides the freeze-dried preparations of water solution containing L-ascorbyl-2-phosphate-6-fatty acid and L-alanyl-L-glutamine.

The invention provides a cosmetic composition containing L-ascorbic acid. The composition comprises 5-40 wt% of the L-ascorbic acid, 0.2-2 wt% of a cinnamic acid derivative, 5-10 wt% of a glycol etherand / or alkylene glycol solvent, 1.0-50 wt% of polyvinylpyrrolidone and deionized water. By means of the cosmetic composition prepared from the raw materials in the proportion, the L-ascorbic acid ishigh in long-term stability.

The invention relates to medicine and pharmacology, in particular to liposomal composition of antioxidants suitable for inhalations during lung and upper respiratory tract diseases. The inventive antioxidant composition for inhalations of lungs and upper respiratory tracts is embodied in the form of an emulsion of phospholipides in the form of liposomes, the mean size of the particles of which ranges from 0.2 to 0.4 mkm, wherein dihydroquercitin flavonoid and wheat-germ oil, containing hydrophobic tocopherol antioxidants (vitamin E) and carotinoids, are incorporated in the membranes of said particles and the aqueous phase of the emulsion contains potassium chloride and antioxidants in the form of a cevitamic acid (vitamin C), N-acetyl, L-cystein and potassium bensoate. Said antioxidant composition is selected taking into account the possibility of introducing minimum doses of individual vitamins in such a way that the content of an active unoxidised form of antioxidants is not reduced during storage.

The present invention comprises the use of sulfite additives to reduce discoloration of L-ascorbic acid produced from acid or aqueous solutions of 2-keto-L-gulonic acid. In one aspect, the present invention comprises a continuous process for producing L-ascorbic acid from an aqueous solution of 2-keto-L-gulonic acid. The use of sulfite additives reduces product stream color and improves product recovery by binding to high molecular weight reaction by-products. In a continuous process, the reaction stream is separated from residual sulfite and sulfite-bound by-products products to produce a product stream enriched in aqueous ascorbic acid for recovery, and an enriched 2-keto-L-gulonic acid stream which is recycled to the reactor. The in situ use of sulfite additives during the reaction increases the overall yield of L-ascorbic ascorbic acid, with no loss in selectivity of the synthesis.

The invention provides vitamin C aliphatic acid diester and a preparation method thereof and relates to L-ascorbic acid diester and a preparation method thereof. According to the vitamin C aliphatic acid diester, the problems that vitamin C monoester is difficulty compatible with medicines, and vitamin C tetraester is weak in oxidation resistance are solved. The structural formula of the vitamin C aliphatic acid diester is shown in the specification. The preparation method of the vitamin C aliphatic acid diester comprises the following steps: after vitamin C is mixed with ethyl acetate, adding pyridine and a phase transfer catalyst, dropwise adding fatty acyl chloride into a reaction system, maintaining the dropwise adding speed until the dropwise adding is finished, continuing to react to separate a water layer and an oil layer, washing with water, and evaporating to separate ethyl acetate, so as to obtain a colorless oily vitamin C aliphatic acid diester crude product; and (2) dissolving the colorless oily vitamin C aliphatic acid diester crude product by virtue of a methanol-water mixed solvent, cooling to separate a methanol layer and a product layer, and removing methanol and ethyl acetate, so as to obtain a pure product, namely the vitamin C aliphatic acid diester. According to the preparation method, the compatibility and the oxidation resistance of the vitamin C aliphatic acid diester are obviously enhanced, and the purity of the product is improved. The preparation method is used for preparing the vitamin C aliphatic acid diester.

The invention relates to a new substance, namely zinc ascorbate hydrogen citrate, as well as a preparation method and an application thereof. The preparation method of the zinc ascorbate hydrogen citrate is characterized by comprising the following steps: (1) weighing raw materials, namely citric acid monohydrate, ascorbic acid, zinc oxide and water, and putting into a reaction kettle, wherein the weight ratio of the substances, namely the citric acid monohydrate, the ascorbic acid and the zinc oxide is 3: 1: 4; (2) starting a machine for performing chemical reaction for half an hour; (3) stopping the machine for half an hour, adding ethanol and enabling the chemical reaction to be mature; and (4) starting the machine for half an hour, and releasing the zinc ascorbate hydrogen citrate. The zinc ascorbate hydrogen citrate prepared by the preparation method provided by the invention can be dissolved in water, be conductive to absorption by people and animals, and be used as a zinc supplement Vc anti-oxidation preservative, a zinc supplement Vc food additive or medicines for treating bad appetite, dysplasia, stomach diseases, bronchitis, asthma, pneumonia, hepatitis, liver cancer and hypertension.

One of the object of the present invention is to provide an L-ascorbic acid 2-phosphate metal salt, which causes no clouding and scarcely precipitates or deposits even when added to a cosmetic material or the like having blended therein an organic acid. Disclosed herein is an L-ascorbic acid-2-phosphate metal salt with a low calcium content characterized in that the content of a calcium compound is 500 ppm or less in terms of calcium ion, and production process thereof.

A cosmetic containing L-ascorbic acid 2-phosphate sodium salt that excels in long-term storage stability. In particular, there is provided a cosmetic characterized in that L-ascorbic acid 2-phosphate sodium salt (A) and at least one compound (B) selected from the group consisting of arginine, urea and triethanolamine are contained in a mixing mass ratio of (A):(B) ranging from 1:0.001 to 1:0.5.

A cosmetic containing L-ascorbic acid 2-phosphate sodium salt that excels in long-term storage stability. In particular, there is provided a cosmetic characterized in that L-ascorbic acid 2-phosphate sodium salt (A) and at least one compound (B) selected from the group consisting of arginine, urea and triethanolamine are contained in a mixing mass ratio of (A):(B) ranging from 1:0.001 to 1:0.5.

The invention relates to a method for preparing L-ascorbic acid or D-erythorbic acid carboxylate by using acyl chloride. According to the method, with DMAc (N,N-dimethylacetamide) or NMP (N-methyl pyrrolidone) as a solvent, a catalyst and an acid-binding agent in reaction of carboxylic acid and SOCl2, acryl chloride directly reacts with L-ascorbic acid or D-erythorbic acid without being separated to prepare L-ascorbic acid or D-erythorbic acid carboxylate. Compared with the existing acryl chloride method, the method disclosed by the invention has the characteristics of simple operation, little dosage of SOCl2, short reaction period, mild reaction conditions, high reaction yield, environmental friendliness and the like, and a used solvent does not need to be dried in advance.

The invention belongs to the technical field of catalyst preparation, and is a preparation method of tris[tris(m-sodium phenyl sulfonate phenyl)phosphine]rhodium chloride catalyst. The method is as follows: under nitrogen protection, ascorbate and rhodium chloride are mixed Dissolve it in absolute alcohol, and add it into the aqueous solution of tris(m-sodium sulfonate phenyl)phosphine at 60°C to 100°C to react for 0.5 hours to 2 hours. After the reaction was completed, alcohol precipitation was added in the reaction solution, and the target catalyst tris[tris(m-sulfonate phenyl)phosphine]rhodium chloride was separated and recovered. The invention has the advantages that the method has the advantages of easy availability of raw materials, less dosage of ligand tris(m-sodium sulfonate phenyl)phosphine, simple preparation process, high product yield and good quality. Catalysts can be used in hydroformylation reactions, as well as in hydrogenation and carbon-carbon coupling reactions.

A selective chemotherapy method incldues the step of contacting tumor cells with a mineral ascorbate / vitamin C metabolite composition. A chemotherapeutic composition comprises the mineral ascorbate / vitamin C metabolite composition in a pharmacologically acceptable intravenous carrier.

The present invention comprises the use of sulfite additives to reduce discoloration of L-ascorbic acid produced from acid or aqueous solutions of 2-keto-L-gulonic acid. In one aspect, the present invention comprises a continuous process for producing L-ascorbic acid from an aqueous solution of 2-keto-L-gulonic acid. The use of sulfite additives reduces product stream color and improves product recovery by binding to high molecular weight reaction by-products. In a continuous process, the reaction stream is separated from residual sulfite and sulfite-bound by-products products to produce a product stream enriched in aqueous ascorbic acid for recovery, and an enriched 2-keto-L-gulonic acid stream which is recycled to the reactor. The in situ use of sulfite additives during the reaction increases the overall yield of L-ascorbic ascorbic acid, with no loss in selectivity of the synthesis.